These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Franz DN; Agricola KD; Tudor CA; Krueger DA J Child Neurol; 2013 May; 28(5):602-7. PubMed ID: 22805244 [TBL] [Abstract][Full Text] [Related]
23. Everolimus for astrocytomas in tuberous sclerosis complex. Geoerger B; Blockus H Lancet; 2013 Jan; 381(9861):95-6. PubMed ID: 23158521 [No Abstract] [Full Text] [Related]
24. Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus. Sparagana SP; Wilkes DC; Thompson CE; Bowers DC Pediatr Neurol; 2010 Jun; 42(6):443-6. PubMed ID: 20472200 [TBL] [Abstract][Full Text] [Related]
25. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707 [TBL] [Abstract][Full Text] [Related]
26. [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma]. Zhou WN; Chen ZP; You C; Mu YG; Sai K; Zhang JY; Zhang XH; Cheng JJ; Xu HC Ai Zheng; 2004 Nov; 23(11 Suppl):1555-60. PubMed ID: 15566679 [TBL] [Abstract][Full Text] [Related]
27. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis? Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185 [TBL] [Abstract][Full Text] [Related]
28. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511 [TBL] [Abstract][Full Text] [Related]
33. Neuro-oncology: a selected review of ASCO 2011 abstracts. Chamberlain MC Expert Rev Neurother; 2011 Oct; 11(10):1371-7. PubMed ID: 21955193 [TBL] [Abstract][Full Text] [Related]
34. mTOR in tuberous sclerosis and other neurological disorders. Franz DN Epilepsia; 2007 Aug; 48(8):1630-1; author reply 1632-4. PubMed ID: 17692052 [No Abstract] [Full Text] [Related]
35. The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent. Miller JM; Wachsman A; Haker K; Majlessipour F; Danielpour M; Puliyanda D Pediatr Nephrol; 2015 Jan; 30(1):173-7. PubMed ID: 25194630 [TBL] [Abstract][Full Text] [Related]
36. The evolving experience using everolimus in clinical transplantation. Formica RN; Lorber KM; Friedman AL; Bia MJ; Lakkis F; Smith JD; Lorber MI Transplant Proc; 2004 Mar; 36(2 Suppl):495S-499S. PubMed ID: 15041395 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of mTOR in tuberous sclerosis. Sampson JR Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643 [TBL] [Abstract][Full Text] [Related]